• Renin Inhibition Mitigates Diabetic Sarcopenia via Glucose U

  2026-06-26

  This study demonstrates that targeting the renin-angiotensin system with tanshinone IIA (Tan IIA) improves skeletal muscle function in diabetic sarcopenia by enhancing glucose uptake and reducing insulin resistance. By integrating biochemical, cellular, and animal model evidence, the research clarifies the mechanistic link between RAS activity, AGEs/RAGE signaling, and muscle metabolic health—offering new avenues for diabetes-related muscle preservation strategies.

• Antibody Targeting of SCUBE3 Suppresses Tumor Progression

  2026-06-26

  This study uncovers SCUBE3 as a critical driver of cancer cell survival, therapy resistance, and immune evasion. By developing a first-in-class neutralizing antibody against SCUBE3, the authors demonstrate potent suppression of oncogenic signaling and restoration of antitumor immunity, highlighting a promising pan-cancer therapeutic strategy.

• Hesperadin (SKU A4118): Reliable Aurora B Kinase Inhibition

  2026-06-25

  This article delivers actionable, scenario-driven guidance for researchers using Hesperadin (SKU A4118) as an Aurora B kinase inhibitor in cell viability and mitotic assays. Emphasizing experimental reproducibility, mechanistic clarity, and practical protocol tips, it connects the product's unique properties to real-world laboratory challenges, supporting informed decisions for cancer research and cell cycle studies.

• SB525334: Mechanistic Insights and Novel Protocols in TGF-be

  2026-06-25

  Explore how SB525334, a potent TGF-beta1 receptor inhibitor, is redefining experimental strategy in fibrosis and wound healing research. This article reveals advanced mechanistic insights and practical protocols not found in existing guides.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-24

  Schwartz (2022) introduces a rigorous distinction between relative viability and fractional viability in evaluating anti-cancer drugs, revealing that these commonly conflated metrics capture different biological effects. This insight improves the accuracy and reproducibility of in vitro drug response studies, directly informing assay optimization for agents like chlorambucil.

• Molnupiravir Suppresses Bourbon Virus Pathology in Mice Mode

  2026-06-23

  This study presents compelling evidence that molnupiravir, a broad-spectrum nucleoside analogue, inhibits Bourbon virus (BRBV) replication and protects mice from lethal infection. The findings establish a preclinical framework for evaluating antiviral strategies against emerging tick-borne RNA viruses without approved treatments.

• Maraviroc (UK-427857): Applied Workflows in CCR5 Research

  2026-06-23

  Maraviroc (UK-427857) stands out as a high-affinity CCR5 antagonist, uniquely enabling precise inhibition of chemokine signaling in both virology and inflammation models. This guide unpacks optimized workflows, novel RA insights, and practical troubleshooting—anchored by APExBIO’s trusted manufacturing standards.

• AMPK Controls Macrophage Polarization in Obesity-Related Ast

  2026-06-22

  This study demonstrates that AMPK activation suppresses M1 macrophage polarization and attenuates airway inflammation in obesity-related asthma models, implicating the JAK2/STAT3 pathway. The findings offer mechanistic insight and suggest AMPK as a promising target for therapeutic intervention in steroid-resistant asthma phenotypes.

• Amitriptyline HCl: Mechanisms and Benchmarks for Receptor Mo

  2026-06-22

  Amitriptyline HCl is a well-characterized tricyclic compound with high affinity for serotonin and norepinephrine receptors. Its verified potency and solubility support rigorous neuropharmacology research. This article provides a protocol-driven, evidence-based overview for mechanistic and translational studies.

• Viral vIRD-Mediated RIPK3 Degradation Modulates Inflammation

  2026-06-21

  Liu et al. identified a class of viral proteins (vIRD) in orthopoxviruses that induce proteasomal degradation of the necroptosis adaptor RIPK3, thereby regulating virus-induced inflammation. This discovery elucidates a key host-pathogen interaction mechanism with implications for understanding viral pathogenesis and innate immunity.

• Chloroquine Diphosphate (SKU A8628): Reliable Autophagy Assa

  2026-06-20

  This article delivers scenario-driven guidance for biomedical researchers using Chloroquine diphosphate (SKU A8628) in cell viability, proliferation, and cytotoxicity assays. By integrating real laboratory challenges, evidence-backed protocol advice, and comparative vendor insights, it demonstrates how this compound streamlines autophagy modulation and therapeutic sensitization in cancer research.

• Cyanidin Chloride: Anthocyanin Polyphenolic Antioxidant in S

  2026-06-19

  Cyanidin Chloride brings precision and reproducibility to oxidative stress and inflammatory skin disease research as a high-purity anthocyanin polyphenolic antioxidant. Its robust cell protectant and barrier-restorative effects are now validated by advanced workflows in psoriasis and beyond. This guide translates key findings and troubleshooting strategies into actionable protocols for modern cellular and preclinical studies.

• Saquinavir in Advanced HIV Protease Inhibitor Assays: Depth

  2026-06-19

  Explore the pivotal role of Saquinavir as an HIV protease inhibitor in cutting-edge antiretroviral drug research. This article uniquely connects permeability assay methodology advances to practical study design, setting new standards for HIV infection research.

• HBsAg-TBK1 Interaction: Suppressed IFN and Induced Early Aut

  2026-06-18

  This study reveals a novel mechanism by which hepatitis B surface antigen (HBsAg) interacts with TANK-binding kinase 1 (TBK1), suppressing type I interferon signaling and promoting early-stage autophagy. These findings clarify how HBV evades innate immunity, advancing our understanding of persistent infection and offering mechanistic insight for research on autophagy and immune modulation.

• RepSox (ALK5 Inhibitor): Precision in iPSC Reprogramming & P

  2026-06-18

  RepSox is a potent and selective ALK5 inhibitor that enables efficient TGF-β pathway inhibition, supporting high-yield induced pluripotent stem cell (iPSC) reprogramming and differentiation. Its use in optimized protocols reduces costs and shortens differentiation timelines for platelet production. APExBIO’s RepSox (A3754) provides reproducible, validated performance in advanced cell biology research.

16000 records 1/1067 page Next 12345 下5页 Last page